Completed PHASE2 INTERVENTIONAL NCT00001929

Treatment of Parkinson's Disease With Eliprodil

NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Conditions Movement Disorders Parkinson Disease

Interventions Eliprodil

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Mar 31, 1999 Completion: Jan 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Movement Disorders and Parkinson Disease and is currently completed. National Institute of Neurological Disorders and Stroke (NINDS) leads this study, which shows 5 recorded versions since 1999 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Neurological Disorders and Stroke (NINDS)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States